Calpeptin
目录号 : GC10342
Calpeptin是一种可逆且可穿透细胞的半胱氨酸组织蛋白酶抑制剂。Calpeptin对钙蛋白酶I和II（猪源）、木瓜蛋白酶以及血小板钙蛋白酶I的ID50值分别为52nM, 34nM, 138nM和20nM。Calpeptin可减轻肌肉细胞中的凋亡和继发性炎症变化。
Cas No.:117591-20-5
Sample solution is provided at 25 µL, 10mM.
Calpeptin is a reversible and cell-permeable cysteine cathepsin inhibitor. The ID50 values of Calpeptin for calpain I and II (porcine), papain, and platelet calpain I are 52nM, 34nM, 138nM, and 20nM, respectively[1]. Calpeptin alleviates apoptosis and secondary inflammatory changes in muscle cells[2].
In vitro, Calpeptin (1 and 5μM; 24h) attenuates apoptosis and secondary inflammatory changes induced by extracellular inflammatory stimulation in the muscle cells[2]. Calpeptin (0, 25, 50 and 100μmol/L; 4 days) inhibited PSC activation and proliferation and promoted PSC apoptosis[3].
In vivo, Calpeptin (1.75mg/kg/day; 1 week; i.p.) effectively reduced the expression of Calpain‐2 and TXNIP/NLRP3 inflammasome-related proteins, improved the decreased pericyte marker (PDGFR‐β) and cognitive impairment in hippocampus of DM rats[4]. Calpeptin (2mg/kg/100μl; 2 or 8 days; i.p.) administration after birth affects synaptic development in neonatal rats by inhibiting the Akt/mTOR signaling pathway, thereby perturbing hippocampal function[5]. Calpeptin (200μg/kg; 4 week; i.p.) is neuroprotective against acrylamide-induced neuropathy in rats[6].
References:
[1] Tsujinaka T, Kajiwara Y, Kambayashi J, et al. Synthesis of a new cell penetrating calpain inhibitor (calpeptin). Biochem Biophys Res Commun. 1988 Jun 30;153(3):1201-8.
[2] Shen J, Xiao W, Zong G, et al. Calpain Inhibitor Calpeptin Improves Pancreatic Fibrosis in Mice with Chronic Pancreatitis by Inhibiting the Activation of Pancreatic Stellate Cells. Curr Mol Pharmacol. 2024;17:e18761429241425.
[3] Nozaki K, Das A, Ray SK, et al. Calpeptin attenuated apoptosis and intracellular inflammatory changes in muscle cells. J Neurosci Res. 2011 Apr;89(4):536-43.
[4] Qiao L, Yi S, Li T, et al. Calpeptin improves the cognitive function in Alzheimer's disease-like complications of diabetes mellitus rats by regulating TXNIP/NLRP3 inflammasome. J Diabetes Investig. 2024 Oct;15(10):1365-1376.
[5] Song ZJ, Yang SJ, Han L, et al. Postnatal calpeptin treatment causes hippocampal neurodevelopmental defects in neonatal rats. Neural Regen Res. 2019 May;14(5):834-840.
[6] Su B, Guan Q, Wang M, et al. Calpeptin is neuroprotective against acrylamide-induced neuropathy in rats. Toxicology. 2018 May 1;400-401:1-8.
Calpeptin是一种可逆且可穿透细胞的半胱氨酸组织蛋白酶抑制剂。Calpeptin对钙蛋白酶I和II（猪源）、木瓜蛋白酶以及血小板钙蛋白酶I的ID50值分别为52nM, 34nM, 138nM和20nM[1]。Calpeptin可减轻肌肉细胞中的凋亡和继发性炎症变化[2]。
在体外实验中，Calpeptin（1和5μM; 24小时）可减轻肌肉细胞由细胞外炎症刺激诱导的凋亡和继发性炎症变化[2]。Calpeptin（0, 25, 50和100μmol/L; 4天）抑制了胰星状细胞（PSC）的激活和增殖，并促进PSC凋亡[3]。
在体内实验中，Calpeptin（1.75mg/kg/天; 1周; 腹腔注射）有效降低了糖尿病大鼠海马中Calpain-2和TXNIP/NLRP3炎症体相关蛋白的表达，改善了降低的周细胞标记物（PDGFR-β）和认知障碍[4]。出生后给予Calpeptin（2mg/kg/100μl; 2天或8天; 腹腔注射）可通过抑制Akt/mTOR信号通路影响新生大鼠的突触发育，从而扰乱海马体功能[5]。Calpeptin（200μg/kg; 4周; 腹腔注射）对丙烯酰胺诱导的大鼠神经病变具有神经保护作用[6]。
| Cell experiment [1]: | |
Cell lines | L6 rat myoblasts |
Preparation Method | When the L6 rat myoblasts reached 50%-60% confluency, they were washed twice with phosphate-buffered saline (PBS), pH 7.4. The medium was then changed to DMEM containing 1% fetal bovine serum (FBS) overnight, after which recombinant rat interferon-γ (500units/ml) or recombinant rat tumor necrosis factor-α (100ng/ml) was added. The myoblasts were treated with interferon-γ for 6, 12, 24 or 48h under the conditions of 37°C, 5% CO₂, and full humidity. To observe the effect of calpain inhibition, various doses of Calpeptin (1 and 5μM) were added 5min after exposure to interferon-γ (500units/ml) or tumor necrosis factor-α (100ng/ml). The myoblasts were treated with interferon-γ or tumor necrosis factor-α (100ng/ml) or/and Calpeptin for 24h under the conditions of 37°C, 5% CO₂, and full humidity. Subsequently, the cells were used for the detection of apoptotic changes and the expression of specific proteins. |
Reaction Conditions | 1 and 5μM; 24h |
Applications | Calpeptin attenuates apoptosis and secondary inflammatory changes induced by extracellular inflammatory stimulation in the muscle cells. |
| Animal experiment [2]: | |
Animal models | Sprague Dawley (SD) male rats |
Preparation Method | The diabetic (DM) rat model was constructed by a high-fat and high-sugar (HFHS) diet combined with streptozotocin (STZ). Eight-week-old Sprague-Dawley (SD) rats were fed with a HFHS diet (containing 20% sucrose, 10% fat, 2% cholesterol, and 1% sodium cholate) for 4 weeks. After 4 weeks of the HFHS diet, the rats were fasted for 20h and then intraperitoneally injected with streptozotocin at a dose of 30mg/kg/day for 5 consecutive days. After fasting for 8h, blood glucose levels were measured using a portable glucometer. When the blood glucose levels were ≥16.7mM, the rats were considered to be diabetic rats. After 4 weeks of the HFHS diet, the rats were intraperitoneally injected with 1.75mg/kg/day of Calpeptin for 1 week. As a control group, rats were fed with a normal diet and intraperitoneally injected with phosphate-buffered saline (PBS). |
Dosage form | 1.75mg/kg/day; 1 week; i.p. |
Applications | Calpeptin effectively reduced the expression of Calpain‐2 and TXNIP/NLRP3 inflammasome-related proteins, improved the decreased pericyte marker (PDGFR‐β) and cognitive impairment in hippocampus of DM rats. |
References: | |
| Cas No. | 117591-20-5 | SDF | |
| 化学名 | benzyl N-[4-methyl-1-oxo-1-(1-oxohexan-2-ylamino)pentan-2-yl]carbamate | ||
| Canonical SMILES | CCCCC(C=O)NC(=O)C(CC(C)C)NC(=O)OCC1=CC=CC=C1 | ||
| 分子式 | C20H30N2O4 | 分子量 | 362.47 |
| 溶解度 | ≥ 87.6 mg/mL in DMSO, ≥ 96.6 mg/mL in EtOH | 储存条件 | Desiccate at 4°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.7588 mL | 13.7942 mL | 27.5885 mL |
| 5 mM | 0.5518 mL | 2.7588 mL | 5.5177 mL |
| 10 mM | 0.2759 mL | 1.3794 mL | 2.7588 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
